How Pfizer Inc. Could Push AstraZeneca plc Down To 3,100p

AstraZeneca plc (LON:AZN) is a volatile business that will disappoint shareholders if Pfizer Inc. (NYSE:PFE) doesn’t make a comeback, argues Alessandro Pasetti.

| More on:

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

When investing, your capital is at risk. The value of your investments can go down as well as up and you may get back less than you put in.

Read More

The content of this article is provided for information purposes only and is not intended to be, nor does it constitute, any form of personal advice. Investments in a currency other than sterling are exposed to currency exchange risk. Currency exchange rates are constantly changing, which may affect the value of the investment in sterling terms. You could lose money in sterling even if the stock price rises in the currency of origin. Stocks listed on overseas exchanges may be subject to additional dealing and exchange rate charges, and may have other tax implications, and may not provide the same, or any, regulatory protection as in the UK.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

astrazeneca2Now that Pfizer (NYSE: PFE.US) has decided to allocate billions of capital to buy back its own shares, AstraZeneca (LSE: AZN) (NYSE: AZN.US) shareholders are faced with a big dilemma: should they stick with their bets?

The answer is no, in my view. A more relevant question is: how long will it take for their shares — which trade at £44 — to drop to £31?

Get Ready For The Drop

Between 2011 and 2013, the revenue and profits of Astra plummeted as many of its popular drugs went off-patent, but Astra continued to pay a healthy dividend. During that period, the shares of Astra traded in the £30-£36 range, and rose by 19.5%.

Astra stock has struggled to trade higher than £36 for about a decade until the end of 2013. That price is not only my best-case scenario right now, but is also the level where the shares changed hands before takeover rumours emerged in January.

Analysts 

For the record, in November and December 2013, only a few weeks before takeover rumours emerged, analysts’ estimates were split as follows: a) a bull-case scenario, with a price target of £37; b) a base-case scenario, with an average price target of £32; c) and a bear-case scenario, with a price target of £25.

(Those price targets were maintained for most of 2013. There is no evidence, in my view, that Astra’s pipeline of drugs will deliver the growth rate that is necessary to justify a valuation above £36 a share.)

Earnings Per Share, Operating And Net Income Margins

In 2011 and 2012, Astra’s earnings per share (EPS) were much higher than the EPS that Astra is expected to report this year, in 2015 and in 2016. The dividend is still appealing, you may argue, but is not expected to skyrocket anytime soon.

Astra stock is pricey based on several trading metrics, but there’s more you should know before assessing its fair value. Even if Astra grows according to bullish market estimates until the end of 2017, it won’t be able to match the operating and net income margins that it reported in 2012, when its stock traded in the £25-£31 range.

If analysts are right, the net income margin of Astra in 2017 will be 13 percentage points below its net profitability in 2012. That means that cash flows will be less supportive of dividend payments. In fact, I believe Astra will be forced to cut its payout next year or earlier. Then, a 2015 price target of £31 makes a lot of sense.

This Isn’t Enough?

What Astra’s stock price tells us is that investors are aware of the possibility that Pfizer — whose quarterly results beat expectations on Tuesday — will not show up with a blown-out offer. 

And even if Pfizer makes a comeback, how many investors will agree to receive 50% or more of the offer price in Pfizer stock? Surely, the cash portion of any potential offer will be lower than 50%. Then why would anybody want to hold stock in a slow-growth conglomerate whose management, rather than bidding up for a key target, decide to splash out $11 billion on a stock buyback?

Is that you? That’s certainly not me! 

Should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice.

Alessandro Pasetti has no position in any shares mentioned. The Motley Fool UK has no position in any of the shares mentioned. We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

Black woman using loudspeaker to be heard
Investing Articles

I was right about the Barclays share price! Here’s what I think happens next

Jon Smith explains why he still feels the Barclays share price is undervalued and flags up why updates on its…

Read more »

Investing Articles

Where I’d start investing £8,000 in April 2024

Writer Ben McPoland highlights two areas of the stock market that he would target if he were to start investing…

Read more »

View of Tower Bridge in Autumn
Investing Articles

Ahead of the ISA deadline, here are 3 FTSE 100 stocks I’d consider

Jon Smith notes down some FTSE 100 stocks in sectors ranging from property to retail that he thinks could offer…

Read more »

Young female business analyst looking at a graph chart while working from home
Investing Articles

Why I think Rolls-Royce shares will pay a dividend in 2024

Stephen Wright thinks Rolls-Royce shares are about to pay a dividend again. But he isn’t convinced this is something investors…

Read more »

Investing Articles

1 of the best UK shares to consider buying in April

Higher gold prices and a falling share price have put this FTSE 250 stock on Stephen Wright's list of UK…

Read more »

Person holding magnifying glass over important document, reading the small print
Investing Articles

The market is wrong about this FTSE 250 stock. I’m buying it in April

Stephen Wright thinks investors should look past a 49% decline in earnings per share and consider investing in a FTSE…

Read more »

Black father and two young daughters dancing at home
Investing Articles

1 FTSE 250 stock I own, and 1 I’d love to buy

Our writer explains why she’s eyeing up this FTSE 250 growth phenomenon, and may buy more shares in this property…

Read more »

View of Tower Bridge in Autumn
Investing Articles

The FTSE 100 is closing in on 8,000 points! Here’s what I’m buying before it’s too late!

As the FTSE 100 keeps gaining momentum, this Fool is on the lookout for bargains. Here's one stock he'd willingly…

Read more »